FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christopher C. Nessel

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Jonathan Piccini; Daniel E Singer; Susanna R Stevens; Richard C Becker; Günter Breithardt; Robert M Califf; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Yuliya Lokhnygina; Kenneth W Mahaffey; Christopher C. Nessel; Manesh R Patel
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial.
Manesh R Patel; Jonathan Piccini; Daniel E Singer; Zhongxin Zhang; Surya Mohanty; Christopher C. Nessel; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Robert M Califf; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Anne S Hellkamp; Yuliya Lokhnygina; Kenneth W Mahaffey
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Jonathan Piccini; Daniel E Singer; Susanna R Stevens; Richard C Becker; Günter Breithardt; Robert M Califf; Yuchiao Chang; Keith A A Fox; Alan S Go; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Yuliya Lokhnygina; Kenneth W Mahaffey; Christopher C. Nessel; Manesh R Patel
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christopher C. Nessel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jonathan Piccini; Daniel E Singer; Susanna R Stevens; Richard C Becker; Günter Breithardt; Robert M Califf; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Yuliya Lokhnygina; Kenneth W Mahaffey; Christopher C. Nessel; Manesh R Patel
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial.
Journal of the American College of Cardiology 2013;61(19):1998-2006.
2013: Manesh R Patel; Jonathan Piccini; Daniel E Singer; Zhongxin Zhang; Surya Mohanty; Christopher C. Nessel; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Robert M Califf; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Anne S Hellkamp; Yuliya Lokhnygina; Kenneth W Mahaffey
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Journal of the American College of Cardiology 2013;61(6):651-8.
2013: Jonathan Piccini; Daniel E Singer; Susanna R Stevens; Richard C Becker; Günter Breithardt; Robert M Califf; Yuchiao Chang; Keith A A Fox; Alan S Go; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Yuliya Lokhnygina; Kenneth W Mahaffey; Christopher C. Nessel; Manesh R Patel
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Circulation 2013;127(2):224-32.
2011: Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C. Nessel; John F Paolini; Manesh R Patel; Jonathan P Piccini; Daniel E Singer; Daniel Wojdyla; Richard C Becker; Robert M Califf
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
European heart journal 2011;32(19):2387-94.
2011: Manesh R Patel; Jonathan P Piccini; Daniel E Singer; Richard C Becker; Scott Darrell Berkowitz; Günter Breithardt; Robert M Califf; Keith A A Fox; Jyotsna Garg; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C. Nessel; Guohua Pan; John F Paolini
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
The New England journal of medicine 2011;365(10):883-91.
2006: Harvey D White; Neal S Kleiman; Kenneth W Mahaffey; Yuliya Lokhnygina; Karen S Pieper; Karen Chiswell; Marc Cohen; Robert A Harrington; Derek P Chew; John L Petersen; Lisa G Berdan; Philip E G Aylward; Christopher C. Nessel; James J Ferguson; Robert M Califf
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
American heart journal 2006;152(6):1042-50.
2005: Christopher C. Nessel
On "the P2 receptors and congenital platelet function defects" (Semin Thromb Hemost 2005;31:168-173).
Seminars in thrombosis and hemostasis 2005;31(5):610.
2005: Christopher C. Nessel
Letter regarding article by Armstrong et al, "Lessons learned from a clinical trial".
Circulation 2005;111(23):e393; author reply e393.
2005: Christopher C. Nessel
On "Current role of antithrombotic agents in the treatment of acute coronary syndromes" (Semin Thromb Hemost 2004;30:627-632).
Seminars in thrombosis and hemostasis 2005;31(2):248.
2004: John L Petersen; Kenneth W Mahaffey; Richard C Becker; Shaun G Goodman; Neal S Kleiman; A J Marian; Gregg W Stone; Alexandra J Lansky; A Michael Lincoff; Stanley L Hazen; Christopher C. Nessel; Luis Toro-Figueroa; Lynn Tate; Craig J Reist; Marc Cohen; Robert M Califf; James J Ferguson
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
American heart journal 2004;148(2):269-76.
2004: John L Petersen; Kenneth W Mahaffey; Vic Hasselblad; Elliott M Antman; Marc Cohen; Shaun G Goodman; Anatoly Langer; Michael A Blazing; Anne Le-Moigne-Amrani; James A de Lemos; Christopher C. Nessel; Robert A Harrington; James J Ferguson; Eugene Braunwald; Robert M Califf
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
JAMA : the journal of the American Medical Association 2004;292(1):89-96.
2004: James J Ferguson; Robert M Califf; Elliott M Antman; Marc Cohen; Cindy L Grines; Shaun Goodman; Dean J Kereiakes; Anatoly Langer; Kenneth W Mahaffey; Christopher C. Nessel; Paul W Armstrong; Alvaro Avezum; Phil Aylward; Richard C Becker; Luigi Biasucci; Steven Borzak; Jacques Col; Marty J Frey; Ed Fry; Dietrich C Gulba; Sema Guneri; Enrique Gurfinkel; Robert A Harrington; Judith S Hochman; Neal S Kleiman; Martin B Leon; Jose Luis Lopez-Sendon; Carl J Pepine; Witold Ruzyllo; Steven R Steinhubl; Paul S Teirstein; Luis Toro-Figueroa; Harvey White
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
JAMA : the journal of the American Medical Association 2004;292(1):45-54.
1999: Christopher C. Nessel; William L Henry; Balduino Mastrofrancesco; Jonathan S Reichner; Jorge E Albina
Vestigial respiratory burst activity in wound macrophages.
The American journal of physiology 1999;276(6 Pt 2):R1587-94.